“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requests additional Phase III comparative study and safety data for iloperidone.
You may also be interested in...
Novartis Deal Sealed, Vanda Plays Up Injectable Potential
Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.
Novartis Deal Sealed, Vanda Plays Up Injectable Potential
Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.
Vanda’s Fanapt Approval Shows Evolution Of FDA’s Thinking
FDA's approval of Vanda's Fanapt (iloperidone) May 6 means that the bar for new atypical antipsychotic approvals may not be as high as it seemed 10 months ago, when FDA's "not approvable" letter on iloperidone requested an additional comparative trial